Delisting risk
Aspire Biopharma
Developer of sublingual drug and supplement formulations, including aspirin candidates and Buzz Bomb.
$8.51
After-hours close−0.01 (−0.12%)
At close$8.52(+3.15%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | — | −$1.00 | — |
| Aug 2026 | — | — | — |
| May 2026 | — | −$20.57 | — |
| Mar 2026 | — | −$3.15 | — |
The latest year is open to everyone — the 19 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Apr 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| Jun 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | — | −$1.00 | — | — | $63.1K | — |
| Aug 12, 2026 | — | — | — | — | $63.1K | — |
| May 15, 2026 | — | −$20.57 | — | — | $28.4K | — |
| Mar 30, 2026 | — | −$3.15 | — | — | $4.3K | — |
The latest year is open to everyone — the 19 quarters behind it read with an account. Sign in | ||||||
| Nov 14, 2025 | ||||||
| Aug 13, 2025 | ||||||
| May 14, 2025 | ||||||
| Apr 7, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 16, 2024 | ||||||
| Jun 5, 2024 | ||||||
| Mar 11, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 21, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 16, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||